

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (de-173) LADEMIRSEN SODIUM
PRONUNCIATION lad" e mir' sen
THERAPEUTIC CLAIM Treatment of kidney fibrosis; Alport Syndrome
CHEMICAL NAME

1. DNA, d(P-thio)([2'-O-(2-methoxyethyl)]rA-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)-α-L-mannofurano]C-A-T-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)-α-L-mannofurano]C-A-G-T-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)-α-L-mannofurano]C-T-G-A-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)-α-L-mannofurano]U-A-A-G-(3'→4')-[2',5'-anhydro-6'-deoxy-4'-C-(hydroxymethyl)-α-L-mannofurano]C-T-[2'-O-(2-methoxyethyl)]rA), sodium salt (1:18)

STRUCTURAL FORMULA

18 Na⁺ [acatcagtct gauaagcta]

MOLECULAR FORMULA C₂₀₁H₂₃₆N₇₂N_{a18}O₁₀₁P₁₈S₁₈
MOLECULAR WEIGHT 6825
TRADEMARK None as yet
SPONSOR Regulus Therapeutics, Inc.
CODE DESIGNATIONS RG-012, RG456070
CAS REGISTRY NUMBER 1885122-05-3
UNII UWG3VFAQ5CQ

gbk